التفاصيل البيبلوغرافية
| العنوان: |
Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib. |
| المؤلفون: |
Gandhi, Malini M., Ricciuti, Biagio, Harada, Guilherme, Repetto, Matteo, Gildenberg, Melissa S., Singh, Ankit, Li, Yvonne Y., Gagné, Andréanne, Wang, Xinan, Aizer, Ayal, Fitzgerald, Kelly, Nishino, Mizuki, Alessi, Joao, Pecci, Federica, Di Federico, Alessandro, Fisch, Adam, Drilon, Alexander, Nardi, Valentina, Sholl, Lynette, Awad, Mark M. |
| المصدر: |
JCO Precision Oncology; 11/16/2023, Vol. 7, p1-8, 8p |
| مصطلحات موضوعية: |
NON-small-cell lung carcinoma, PROSTATE cancer, NUCLEOTIDE sequencing, CANCER patients, INFORMATION sharing, HEREDITARY cancer syndromes |
| الشركة/الكيان: |
MEMORIAL Sloan-Kettering Cancer Center, DANA-Farber Cancer Institute |
| مستخلص: |
PURPOSE: RET rearrangements and RET activating point mutations represent targetable genomic alterations in advanced solid tumors. However, the frequency and clinicopathologic characteristics of wild-type RET amplification in cancer and its potential role as a targetable oncogenic driver are not well-characterized. METHODS: In two institutional cohorts of patients with solid cancers from the Dana-Farber Cancer Institute (DFCI) and Memorial Sloan Kettering Cancer Center (MSKCC) whose tumors underwent next-generation sequencing (NGS), the frequency and clinicopathologic features of wild-type RET amplification in the absence of RET rearrangements or activating mutations was assessed. The findings were validated using merged data from The Cancer Genome Atlas (TCGA), Genomics Evidence Neoplasia Information Exchange (GENIE), and China Pan-Cancer data sets. RESULTS: The frequency of wild-type RET amplification across all solid cancers was 0.08% (26 of 32,505) in the DFCI cohort, 0.05% (26 of 53,152) in the MSKCC cohort, and 0.25% (71 of 28,623) in the cohort from TCGA, GENIE, and China Pan-Cancer. Cancer types with RET amplification included non–small-cell lung cancer (NSCLC), hepatobiliary cancer, prostate cancer, breast cancer, and others. The median RET copy number in RET -amplified cases was 7.5 (range, 6-36) in the DFCI cohort and 5.7 (range, 4-27.7) in the MSKCC cohort. Among 11 RET -amplified NSCLCs, eight had no other concurrent driver mutations. Finally, we report on a 69-year-old man with recurrent NSCLC harboring high-level wild-type RET amplification (22-28 copies) as the only identified putative genomic driver who experienced both a systemic and intracranial confirmed response to the RET inhibitor selpercatinib. CONCLUSION: Amplification of wild-type RET represents a novel, targetable molecular subset of cancer. This study establishes wild-type RET amplification as a novel, actionable genomic subset of cancer. [ABSTRACT FROM AUTHOR] |
|
Copyright of JCO Precision Oncology is the property of American Society of Clinical Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
